Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

Exact Sciences EXAS continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising.

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

New modelling data from diagnostics company Exact Sciences indicates that its Cologuard test for colorectal cancer (CRC) screening has detected almost 600,000 cases since receiving US Food and ...

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...

Exact Sciences Corporation’s EXAS robust efforts to enhance Cologuard’s growth are poised to help it grow in the upcoming quarters. The company aims to introduce novel solutions that will ...

Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact ...

Exact Sciences EXAS continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising. The stock ...